Interview, Fireside Chat
Geoff Martha, chairman and chief executive officer of Medtronic
- The R&D pipeline is described as the company's most advanced in history, expected to deliver broad and disruptive innovation currently coming to fruition.
- A surgical robot is positioned to become a significant market player competing against Intuitive and Johnson & Johnson within a couple of years, with the intent to disrupt the surgical landscape.
- Development goals include creating self-driving surgical robots that utilize collected video data to provide real-time surgeon feedback before eventually automating procedures.
- A novel catheter-based hypertension therapy is anticipated to materially lower blood pressure by up to 10 millimeters of mercury within a six-month period if clinical results meet expectations, potentially opening a new market.
- Shifts in physician preference toward virtual training technologies such as 5G and augmented reality are expected to dramatically reduce the demand for face-to-face training interactions.
- The company expects to capitalize on hospital customers consolidating their vendor lists to a smaller number of partners.
- Innovation velocity is identified as being rate-limited by data availability rather than technology itself, with future capacity to monitor, diagnose, and personalize therapy tied directly to data acquisition.
- Ongoing cyber threats are expected in the coming year, prompting a strategy involving regular internal security testing, industry collaboration, and regulatory engagement.
- Discussions are underway with major technology companies to leverage AI and machine learning for subcutaneous sensor-based patient monitoring.
- Maintaining rapid partnership and collaboration models from the pandemic era is expected to face challenges due to future economic considerations, though the outlook remains optimistic.
- Open-source ventilator initiatives and partnerships are projected to improve government relations and strengthen stakeholder trust.
- Data privacy strategies focus on assuring consumers that data usage is dedicated to therapy customization, personalization, safety, and product monitoring rather than marketing purposes.